Larimar Therapeutics (Zafgen)

^{Priced, Nasdaq: LRMR}

Biotech developing a treatment for severe obesity and hunger-related disorders.

Industry: Health Care

First Day Return: +23.4%

LRMR

Biotech developing a treatment for severe obesity and hunger-related disorders.

IPO News for Larimar Therapeutics (Zafgen)

Obesity biotech Gelesis does not float shares; $52 million IPO postponed 05/13/15
The latest weight loss capsule: Gelesis files for a $60 million IPO 04/01/15
Diabetes/Alzheimer's biotech Vitae Pharmaceuticals sets terms for $60 million IPO 09/08/14

IPO Data
IPO Date	06/18/2014
Offer Price	IPO Intelligence Only
Price Range	IPO Intelligence Only
Offer Shares (mm)	IPO Intelligence Only
Deal Size ($mm)	$96
Lock-Up Date	IPO Intelligence Only
Street Research	IPO Intelligence Only

Underwriters
IPO Intelligence Only

Company Data
Website www.zafgen.com
Headquarters	Cambridge, MA, United States
Founded	2005
Employees at IPO	11

IPO News for Larimar Therapeutics (Zafgen)

Larimar Therapeutics (Zafgen) (LRMR) Performance